北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
作者: Lu, Jing1; Lu, Jin2,3; Liu, Aijun4; Fu, Weijun1; Du, Juan1; Huang, Xiaojun2,3; Chen, Wenming4; Hou, Jian1
刊名: BIOMED RESEARCH INTERNATIONAL
发表日期: 2015
10.1155/2015/856704
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biotechnology & Applied Microbiology ; Medicine, Research & Experimental
研究领域[WOS]: Biotechnology & Applied Microbiology ; Research & Experimental Medicine
关键词[WOS]: CLINICAL-FEATURES ; SCORING SYSTEM ; ISS ; GUIDELINES ; SURVIVAL ; STRATIFICATION ; DELETION ; CRITERIA
英文摘要:

The International Staging System (ISS) is the most important prognostic system for multiple myeloma (MM). It was identified in the era of conventional agents. The outcome of MM has significantly changed by novel agents. Thus the applicability of ISS system in the era of novel agents in Chinese patients needs to be demonstrated. We retrospectively analyzed the clinical outcomes and prognostic significance of ISS system in 1016 patients with newly diagnosed multiple myeloma in Chinese patients between 2008 and 2012, who received bortezomib-or thalidomide-based regimens as first-line therapy. The median overall survival (OS) of patients for ISS stages I/II/III was not reached/55.4 months/41.7 months (p < 0.001), and the median progression-free survival (PFS) was 30/29.5/25 months (p = 0.072), respectively. Statistically significant difference in survival was confirmed among three ISS stages in thalidomide-based group, but not between ISS stages I and II in bortezomib-based group. These findings suggest that ISS system can predict the survival in the era of novel agents in Chinese MM patients, and bortezomib may have the potential to partially overcome adverse effect of risk factors on survival, especially in higher stage of ISS system.

语种: 英语
所属项目编号: 81172248 ; 81470360 ; 12ZCDZSY17600
项目资助者: Natural Science Foundation of China ; Tian Jin Municipal Special Foundation for Anticancer
WOS记录号: WOS:000365925600001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65843
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Second Mil Med Univ, Dept Hematol, Myeloma & Lymphoma Ctr, Changzheng Hosp, Shanghai 200003, Peoples R China
2.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
3.Peking Univ, Inst Hematol, Beijing 100044, Peoples R China
4.Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing 100020, Peoples R China

Recommended Citation:
Lu, Jing,Lu, Jin,Liu, Aijun,et al. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis[J]. BIOMED RESEARCH INTERNATIONAL,2015.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Lu, Jing]'s Articles
[Lu, Jin]'s Articles
[Liu, Aijun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Lu, Jing]‘s Articles
[Lu, Jin]‘s Articles
[Liu, Aijun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace